28 related articles for article (PubMed ID: 21913377)
1. Topoisomerase IIα immunoexpression in feline mammary carcinomas: A correlation with Ki67 immunoexpression and the mitotic count.
Łopuszyński W; Brzana A; Szczubiał M; Bulak K; Śmiech A
Res Vet Sci; 2023 Nov; 164():104992. PubMed ID: 37657395
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.
Miura Y; Kaira K; Sakurai R; Imai H; Tomizawa Y; Sunaga N; Minato K; Hisada T; Oyama T; Yamada M
Oncol Lett; 2017 Aug; 14(2):2369-2378. PubMed ID: 28789453
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 induces the activities of DNA topoisomerase I and DNA topoisomerase II in HuT 78 cells.
Pham MH; Kondapalli N; Reckord CL; Foglesong PD
Biochem Biophys Res Commun; 2009 Dec; 390(3):577-80. PubMed ID: 19818738
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers.
Lan T; Xue X; Dunmall LC; Miao J; Wang Y
Aging (Albany NY); 2021 Apr; 13(8):12273-12293. PubMed ID: 33903283
[TBL] [Abstract][Full Text] [Related]
5. Identification of differentially expressed genes in non-small cell lung cancer.
Wang K; Chen R; Feng Z; Zhu YM; Sun XX; Huang W; Chen ZN
Aging (Albany NY); 2019 Dec; 11(23):11170-11185. PubMed ID: 31816603
[TBL] [Abstract][Full Text] [Related]
6. The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition.
Zhang S; Jiang H; Xu Z; Jiang Y; She Y; Huang X; Feng S; Chen W; Chen S; Chen Y; Qiu G; Zhong S
Am J Cancer Res; 2019; 9(10):2233-2248. PubMed ID: 31720085
[TBL] [Abstract][Full Text] [Related]
7. Identification of crucial miRNAs and genes in esophageal squamous cell carcinoma by miRNA-mRNA integrated analysis.
Zhong X; Huang G; Ma Q; Liao H; Liu C; Pu W; Xu L; Cai Y; Guo X
Medicine (Baltimore); 2019 Jul; 98(27):e16269. PubMed ID: 31277149
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes.
Abdo J; Bertellotti CA; Cornell DL; Agrawal DK; Mittal SK
Front Oncol; 2017; 7():151. PubMed ID: 28770168
[TBL] [Abstract][Full Text] [Related]
9. Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Hou GX; Liu P; Yang J; Wen S
PLoS One; 2017; 12(3):e0174515. PubMed ID: 28355294
[TBL] [Abstract][Full Text] [Related]
10. Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.
Ali Y; Abd Hamid S
Tumour Biol; 2016 Jan; 37(1):47-55. PubMed ID: 26482620
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis.
Yu Y; Ding S; Liang Y; Zheng Y; Li W; Yang L; Zheng X; Jiang J
Exp Ther Med; 2014 Jun; 7(6):1578-1582. PubMed ID: 24926347
[TBL] [Abstract][Full Text] [Related]
12. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II alpha expression in esophageal squamous cell carcinoma.
Ohashi Y; Sasano H; Yamaki H; Shizawa S; Kikuchi A; Shineha R; Akaishi T; Satomi S; Nagura H
Anticancer Res; 1999; 19(3A):1873-80. PubMed ID: 10470130
[TBL] [Abstract][Full Text] [Related]
14. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
15. Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas.
Xu XL; Zheng WH; Fu ZX; Li ZP; Xie HX; Li XX; Jiang LH; Wang Y; Zhu SM; Mao WM
Med Oncol; 2015 Jan; 32(1):396. PubMed ID: 25432700
[TBL] [Abstract][Full Text] [Related]
16. Impact of Topoisomerases Complex Deregulation on Head and Neck Carcinoma Genomic Instability.
Kyrodimos E; Chrysovergis A; Mastronikolis N; Tsiambas E; Ragos V; Peschos D; Spyropouloy D; Pantos P; Niotis A; Papanikolaou V
Anticancer Res; 2021 Jun; 41(6):2773-2779. PubMed ID: 34083267
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer.
Hanagiri T; Ono K; Kuwata T; Takenaka M; Oka S; Chikaishi Y; Shigematsu Y; Nagata Y; Shimokawa H; Nakagawa M; Uramoto H; So T; Tanaka F
J UOEH; 2011 Sep; 33(3):205-16. PubMed ID: 21913377
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
